Related Experiment Videos
[Peritonitis due to glycopeptides-resistant Staphylococcus epidermidis]
J Watine1, M Ciobotaru, D Lombart
1Laboratoire de biologie polyvalente, Centre hospitalier Puel, Rodez. j.watine@ch-rodenz.fr
Abstract:
A 71 years old male patient with a history of hypertension for more than 20 years, with chronic kidney failure under intra-peritoneal (IP) dialysis since June 2004, presents in March 2008 with glycopeptides-resistant Staphylococcus epidermidis peritonitis. Under vancomycin IP (alone or in association), clinical symptoms do not entirely subside and bacteria as well as white blood cells do persist in the peritoneal dialysis fluid. Under rifampicin IP, all clinical and laboratory abnormalities disappear. All 4 isolates of S. epidermidis obtained in the laboratory during this infectious episode appear to be susceptible to glycopeptides by the disk diffusion method, but MICs measurements confirm resistance. The only (blood) concentration of vancomycin measured during this episode does neither allow us to affirm, nor to exclude, that sub-inhibitory concentrations of vancomycin facilitated resistance to glycopeptides. This case-report raises the question of the optimal follow-up of those patients with residual kidney function: when, how often, and how do we need to measure blood vancomycin?
Insights
This case report details a patient with resistant Staphylococcus epidermidis peritonitis during peritoneal dialysis. Rifampicin IP proved effective where vancomycin IP failed, highlighting treatment challenges.
Area of Science:
- Nephrology
- Infectious Diseases
- Pharmacology
Background:
- A 71-year-old male with hypertension and chronic kidney failure on peritoneal dialysis presented with peritonitis.
- The patient had a history of dialysis since 2004.
Observation:
- The patient developed peritonitis caused by glycopeptide-resistant Staphylococcus epidermidis.
- Initial treatment with intraperitoneal (IP) vancomycin did not fully resolve symptoms, with persistent bacteria and white blood cells in dialysis fluid.
- Subsequent IP treatment with rifampicin led to complete resolution of clinical and laboratory abnormalities.
Findings:
- Laboratory testing showed Staphylococcus epidermidis isolates were susceptible to glycopeptides by disk diffusion but resistant by MIC measurements.
- A single measured vancomycin blood concentration was insufficient to determine if sub-inhibitory levels contributed to resistance.
- Rifampicin demonstrated efficacy in treating the resistant peritonitis.
Implications:
- This case highlights the challenges of managing glycopeptide-resistant bacterial peritonitis in patients undergoing peritoneal dialysis.
- It raises questions about optimal monitoring strategies for patients with residual kidney function, including the timing and frequency of vancomycin blood level measurements.
- Effective management may require alternative antibiotic strategies beyond standard glycopeptide therapy.
Related Concept Videos
Staphylococcal Skin Infections
Bacterial Gastroenteritis
Mechanism of Antibiotic Resistance in MRSA
Clinical Significance of Antibiotic Resistance
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Inhibitors of Gram-positive Cell Wall Synthesis